共有 1 页
品牌 | 货号 | 包装单位 | 货期 | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|
罗恩 | R019146-50mg | 50mg | 5~7个工作日 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... CYT387 |
98% |
|
|
罗恩 | R019146-10mg | 10mg | 5~7个工作日 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... CYT387 |
98% |
|
|
阿拉丁 | C127224-10mg | 10mg | 现货 |
CYT387,JAK 1/2抑制剂 CYT387 |
Moligand™, ≥98% |
|
|
阿拉丁 | C127224-50mg | 50mg | 现货 |
CYT387,JAK 1/2抑制剂 CYT387 |
Moligand™, ≥98% |
|
|
阿拉丁 | C127224-100mg | 100mg | 现货 |
CYT387,JAK 1/2抑制剂 CYT387 |
Moligand™, ≥98% |
|
|
阿拉丁 | C127224-5mg | 5mg | 现货 |
CYT387,JAK 1/2抑制剂 CYT387 |
Moligand™, ≥98% |
|
|
阿拉丁 | M408149-1ml | 1ml | 现货 |
Momelotinib (CYT387) Momelotinib (CYT387) |
Moligand™, 10mM in DMSO |
|
|
凯为 | JZ00398W-10mg | 10mg | 现货 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... N-(Cyanomethyl)-4-[2-[[4-(4-... |
98% |
|
|
凯为 | JZ00398W-50mg | 50mg | 现货 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... N-(Cyanomethyl)-4-[2-[[4-(4-... |
98% |
|
|
凯为 | JZ00398W-100mg | 100mg | 现货 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... N-(Cyanomethyl)-4-[2-[[4-(4-... |
98% |
|
|
毕得 | BD234397-5mg | 5mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-10mg | 10mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-50mg | 50mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-100mg | 100mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-250mg | 250mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-1mg | 1mg | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
毕得 | BD234397-1g | 1g | 现货 |
N-(氰基甲基)-4-(2-((4-吗啉苯基)氨基)嘧啶... N-(Cyanomethyl)-4-(2-((4-mor... |
98+% |
|
|
韶远 | SY060668-1g | 1g | 现货 |
N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]... N-(Cyanomethyl)-4-[2-[(4-mor... |
≥95% |
|
|
Matrix | MA095905-250mg | 250mg | 3-4周 |
N-(Cyanomethyl)-4-(2-((4-mor... N-(Cyanomethyl)-4-(2-((4-mor... |
95+% | 咨询 | 请联系客服购买! |
Matrix | MA095905-1g | 1g | 3-4周 |
N-(Cyanomethyl)-4-(2-((4-mor... N-(Cyanomethyl)-4-(2-((4-mor... |
95+% | 咨询 | 请联系客服购买! |
源叶 | S40522-5mg | 5mg | 现货 |
CYT387 CYT387 |
≥98% |
|
|
源叶 | S40522-10mg | 10mg | 现货 |
CYT387 CYT387 |
≥98% |
|
|
源叶 | S40522-50mg | 50mg | 现货 |
CYT387 CYT387 |
≥98% |
|
|
源叶 | S40522-200mg | 200mg | 现货 |
CYT387 CYT387 |
≥98% |
|
|
源叶 | T93041-1ml | 1ml | 期货,请咨询 |
Momelotinib (CYT387) Momelotinib (CYT387) |
10mM in DMSO |
|
|
Target Mol | T1849-1mg | 1mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-2mg | 2mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-5mg | 5mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-10mg | 10mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-50mg | 50mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-100mg | 100mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-200mg | 200mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-1mL | 1mL | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Target Mol | T1849-25mg | 25mg | 现货 |
化合物 Momelotinib Momelotini |
99.56% |
|
|
Am | A207449-100mg | 100mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
Am | A207449-1mg | 1mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
Am | A207449-5mg | 5mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
Am | A207449-50mg | 50mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
Am | A207449-250mg | 250mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
Am | A207449-10mg | 10mg | 现货 |
Momelotinib Momelotini |
98+% |
|
|
MCE | HY-10961-200mg | 200mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-100mg | 100mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-50mg | 50mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-10mg | 10mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-10mM*1mL | 10mM*1mL | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-5mg | 5mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|
MCE | HY-10961-1mg | 1mg | 现货 |
Momelotinib Momelotini |
99.37% |
|
|